Gefitinib (ZD1839)

Catalog No.S1025

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gefitinib (ZD1839) Chemical Structure

Gefitinib (ZD1839) Chemical Structure
Molecular Weight: 446.90

Validation & Quality Control

Cited by 87 publications:

11 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Pan EGFR Inhibitor

    AZD8931 (Sapitinib) Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.

  • Most Potent EGFR Inhibitor

    Afatinib (BIBW2992) EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Targets Tyr1173 (NR6W cells) [1] Tyr1173 (NR6wtEGFR cells) [1] Tyr992 (NR6wtEGFR cells) [1] Tyr992 (NR6W cells) [1]
IC50 26 nM 37 nM 37 nM 57 nM
In vitro Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. [1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. [2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KBMmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{eyS2lEPTB;MD6wOVQh|ryPM{LXSVE3PTF4NEez
NIH3T3NYjGRll1TnWwY4Tpc44hSXO|YYm=NHL5W2ExNjJizszNMU[yJIg>M1G4d2ROW09?MX3Jcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF2NDFOwG0>M{mxV|E3PDhyMki0
COS7NEDE[HFHfW6ldHnvckBCe3OjeR?=NIPsOlM6PiEQvF2=NH7X[2tKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?NFvSdHkyPzF5OEeyNi=>
A549MlqwR5l1d3SxeHnjJGF{e2G7MkfUPVYhcA>?MmfrSG1UVw>?NXO5PZozUUN3ME2xN{42QSEQvF2=M2XuNlE5OzF|OEC3
K562M1qwPWN6fG:2b4jpZ{BCe3OjeR?=M1WwWFk3KGh?NGq4XXFFVVORNXfCT29kUUN3ME25MlM3KM7:TR?=NFnabXIyQDNzM{iwOy=>
MDA-MB-231MlXWR5l1d3SxeHnjJGF{e2G7M3nld|k3KGh?Mn\mSG1UVw>?MlLRTWM2OD1|Nj62NUDPxE1?MWmxPFMyOzhyNx?=
MOLT4M2X4ZmN6fG:2b4jpZ{BCe3OjeR?=MUW5OkBpMVTEUXNQNEPrSHpKSzVyPUG1MlAzKM7:TR?=MV6xPFMyOzhyNx?=
MCF7MoPGR5l1d3SxeHnjJGF{e2G7MVy1NEDPxE1?MUK3NkBpNXzZboZLUUN3ME2xNk4xPSEQvF2=MnuzNVg4PzF6MUm=
BT474NEjUeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXsSZMzPzJiaB?=NWfrfXlrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCWFQ4PCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFVmJjOiC5aYToJGVEPTBib3[gNE4{KM7:TR?=MYexPVAzQDR{NB?=
HN5NYDVTYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXOO|IhcA>?Ml7NRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTkWgZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEWFNUCgc4YhOC5yMTFOwG0>NYfpN4Y6OTlyMki0NlQ>
BA/F3M2jLfmN6fG:2b4jpZ{BCe3OjeR?=NH7kOlE4OiCqMoLPR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCC5aYToJGlEPTBib3[gNE4xOTB6IN88US=>NFKwUYoyQTJ|OUKyPS=>
NIH3T3MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfYTVk4OiCqNFj3T4RIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBPUUhxM2SzJINmdGy|IHX4dJJme3Orbneg[ZJDOiCpZX7lJJdqfGhiSVO1NEBw\iByLkW0JO69VQ>?MVuxPVY3PTN5Nx?=
MCF7 MXNGntfoRHfW6ldHnvckBCe3OjeR?=M4nJZ|MxKG2rbh?=MYXJcohq[mm2aX;uJI9nKEKFUmCg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iBzLkGg{txOM4O5XFE6QTN{OU[w
A431NYTCS484T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrrNVAh|ryPNGDmOFQ4OiCqM3zIW2dKPTB;MD61NVQh|ryPNXzDXnh7OTl7Nkm0OlU>
A431M2TpT2tqdmG|ZTDBd5NigQ>?NWPUT5BsOC5zIN88US=>M37xblEhcA>?MWfJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;uNELOfWsyQTl4OUS2OS=>
A431MV\LbY5ie2ViQYPzZZk>NFnVenYyODBizszNMoeyNVAhdWmwMnTCVJJwdG:wZ3XkJIlvcGmkaYTvdpkh[WO2aY\peJkhd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>NYnWWlJ3OTl7Nkm0OlU>
Sf9MWjLbY5ie2ViQYPzZZk>NFHYV40yOCCvaX6=MXjEUXNQMVTJcohq[mm2aX;uJI9nKEWJRmKg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gdoVk\XC2b4KgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN|Mh|ryPMViyNFA2PjR{NR?=
NCI-H1975M161SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVu1JO69VQ>?M1;vWFczKGh?MXfJR|UxRThwMk[g{txOMWGyNFE2OTZ5MB?=
NCI-H1975M4O0fmtqdmG|ZTDBd5NigQ>?M3TUSlExKM7:TR?=MnXhTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44>NVvyR2dCOjBzNUG2O|A>
NCI-H1975M2nve2Z2dmO2aX;uJGF{e2G7M1TUcVExKM7:TR?=M4jVdmlvcGmkaYTpc44hd2ZiRWLCRlIh[XW2b4Doc5NxcG:{eXzheIlwdg>?NFjidXAzODF3MU[3NC=>
NCI-H1975MlPNSpVv[3Srb36gRZN{[Xl?MXS1JO69VQ>?MXi0PEBpNF[4XpNKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S1|NIfMWWIzODF3MU[3NC=>
A375MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETQbms1QCCqNXT6enY2UUN3ME2yNE42PSEQvF2=NFX5WIkzODNyNEWzOy=>
SMMC7721M1\Sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjNcYU1QCCqM2HJWWlEPTB;M{OuNVIh|ryPMVWyNFMxPDV|Nx?=
DU145Mm\6R5l1d3SxeHnjJGF{e2G7MX21JIQ>NFLnXHVFVVORM{D5OmlEPTB;NEKuNVch|ryPMXiyNFQ3PjV3NR?=
MIAPaCa2NFL3b3VEgXSxdH;4bYMhSXO|YYm=MYW1JIQ>MXPEUXNQNUPsbJBpUUN3ME21NE43OiEQvF2=M2fZfVIxPDZ4NUW1
PANC1NFfk[ItEgXSxdH;4bYMhSXO|YYm=MkX6OUBlNX7wNWtKTE2VTx?=NIrYNmlKSzVyPUSwMlQzKM7:TR?=MlW5NlA1PjZ3NUW=
PC9MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDFS2ZTNWSnZnnjbYVvfCCqdX3hckBRSzliY3XscJMhf2m2aDDFR|UxKG:oIECuNFE4KM7:TR?=MmjqNlEzODh6MEK=
PC9NEj4dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHfyc5d1cC2{ZYPpd5RidnRiaIXtZY4hWEN7IHPlcIx{KGW6cILld5NqdmdiRVfGVkBGPzR4X1G3OVAwXDd7MF2gcZV1[W62IIfpeIghTUN3MDDv[kA4KM7:TR?=NWPxeXBjOjF{MEi4NFI>
PC3NIXWbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXOxNEDPxE1?NGfPcWE4OiCqM2iycWROW09?NXTYbFJSUUN3ME23MlQh|ryPMom2NlE{PTN3NE[=
MDA-MB-468MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfSNVAxKM7:TR?=NFfxPGY1QCCqMXLEUXNQM2TJVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5NHO0bWQzOTR{OU[zNi=>
Plasmodium falciparumMn3KdWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?MVSyNVgyPzB2NR?=
NCI-H1993NVXCWZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXvO|IhcA>?MXXEUXNQNX:xV2pYUUN3ME2wMlEh|ryPM2ewOVIyQTF4NEOz
NCI-H292MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYG3NkBpNHrlOFlFVVORNVrEfmxmUUN3ME2wMlAzKM7:TR?=NGLRemgzOTlzNkSzNy=>
A431M{[x[WtqdmG|ZTDBd5NigQ>?NH\xPVQzKGh?MULEUXNQNUfOVGsxUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCHR1[td5RqdXWuYYTl[EBpfW2jbjDBOFMyKHerdHigTWM2OCCxZjCwMlAxOSEQvF2=M2Tn[lIzOTBzMUOy
MCF7NHz4OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnuxNVAxyqEQvHevcWw>NETRTJM1QCCqMWnEUXNQM1Gwb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDveoVz\XiycnXzd4lv\yCHR1\SJIdmdmVid3n0bEBKSzVyIH;mJFEzNjB3IN88US=>NX7GWm9vOjJzMUmxN|A>
BT474MmDjR5l1d3SxeHnjJGF{e2G7NYPLZ2VuOTBizszNMnnKOFghcA>?MVfDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy|MWeyNlE{QDNyOB?=
MCF7M1zxSmN6fG:2b4jpZ{BCe3OjeR?=M4PZZlExKM7:TR?=NXn6[HNLPDhiaB?=MYjDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKE2FRkegZ4VtdHNib4\ldk1mgHC{ZYPzbY5oKEW{YlKyJINmdGy|NWTVe5hJOjJzM{izNFg>
HCC827MkPBT4lv[XOnIFHzd4F6NGDjb|QxNjF{NTFOwG0>MUWyOEBpM3vsbWROW09?M3\NR2lvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9vM3PSOVIzOzN7M{Sy
HCC827MW\LbY5ie2ViQYPzZZk>MVmwMlEzPSEQvF2=Ml7aNlQhcA>?NYjIVWloTE2VTx?=NX71blA1UW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFXyb{BxcG:|cHjvdplt[XSrb36=NW\lR4J6OjJ|M{mzOFI>
HCC827MXrLbY5ie2ViQYPzZZk>MYewMlEzPSEQvF2=NXX3e2FSOjRiaB?=MU\EUXNQMYXJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?MUiyNlM{QTN2Mh?=
A431MoLDT4lv[XOnIFHzd4F6MWexNFAh|ryPM1;vblMxKG2rbh?=NUHZdVljUW6qaXLpeIlwdiCxZjDFS2ZTKGSncnn2[YQh\nKxbTDoeY1idiCDNEOxJINmdGxibXXtZpJidmViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyb3z5MWdtfS2WeYKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAyNjB6IN88US=>M4GxTFIzPjl6N{iy
H460MkXjR5l1d3SxeHnjJGF{e2G7NIrhRmo4OiCqNXjNOGhlUUN3ME21MlU6KM7:TR?=MWOyNlczPzR2OR?=
HT-29NHy5Z3dEgXSxdH;4bYMhSXO|YYm=MXe3NkBpNI\kOWxKSzVyPUOuN|Yh|ryPNUjCc49kOjJ5Mke0OFk>
SGC7901MnT2R5l1d3SxeHnjJGF{e2G7M2DlRlczKGh?NH\RV3lKSzVyPUGwMlI3KM7:TR?=M363WFIzPzJ5NES5
A498NHfNN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jkNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO|aX7nJGVITlJiYX7kJHNTSyC5aYToJGlEPTBib3[gPE43KM7:TR?=MV2yNlgyQDh2OB?=
Calu3M1HTSmN6fG:2b4jpZ{BCe3OjeR?=MUGxNEDPxGdxbVy=NVjydY0{PzJiaB?=NX\aXlVvUUN3ME2xMlYh|ryPM37lZlI{OTF4MU[4
FADUNGnjZmFEgXSxdH;4bYMhSXO|YYm=MVmxNEDPxGdxbVy=M{PLZlczKGh?NHmze4ZKSzVyPUCuNFUh|ryPNV;mS2dwOjNzMU[xOlg>
HCC827NXHYO5VpS3m2b4TvfIlkKEG|c3H5NGXFNo8yOCEQvHevcWw>NFG1d3o4OiCqM{jtR2lEPTB;MD6wNFE2KM7:TR?=MlLnNlMyOTZzNki=
PC9M2PUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVf5N2Q4OTBizsznM41NNYKyO4luPzJiaB?=NFHId5JKSzVyPUCuNFAyPCEQvF2=MnLLNlMyOTZzNki=
Sf9NUX2[WlDU2mwYYPlJGF{e2G7MUOxJIg>MVnEUXNQNH\pdmlKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>Ml\WNlM3OTF4OUG=
16HBE14o-NFjmWWREgXSxdH;4bYMhSXO|YYm=NEHM[IQyOCEQvF2=MmX5O|IhcA>?M{fu[2ROW09?MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>MU[yN|Y3QDR2MR?=
NCI-H1975M33hUmN6fG:2b4jpZ{BCe3OjeR?=M3ziOlExKM7:TR?=M1LVRlczKGh?M{H0VmROW09?NFnobXZEgXSxdH;4bYNqfHliYXfhbY5{fCCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB4LkmxO{DPxE1?Ml\XNlM3Pjh2NEG=
16HBENGDUbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDCdZJsPzJiaB?=NGfjbZhFVVORMn\tRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiBzNljCSUBk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBGT0[UIIfpeIghUUN3MDDv[kAyNjZyMTFOwG0>NHfPO3UzOzd7MkOxPC=>
16HBEMYPGeY5kfGmxbjDBd5NigQ>?M{nUOVExOCEQvF2=MnjaNVUxKG2rbh?=NELDSFBFVVORMnW5TY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>NFPado8zOzd7MkOxPC=>
A549M2jhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1znRVczKGh?M1LNPGROW09?Mo\WRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh|ryPMnewNlM4QTJ|MUi=
SH-SY5YM{XlNmN6fG:2b4jpZ{BCe3OjeR?=MUW3NkBpM2m2XmlEPTB;MUiuNlEh|ryPM3PJdlI{QDdzOUC5
LoVoNUn0SJVDU2mwYYPlJGF{e2G7M37INlIhKGh?M4LMRWROW09?MUHJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB4MjFOwG0>NFXGTXMzOzl|MEm5OC=>
PC9NFTM[4RMcW6jc3WgRZN{[Xl?MmC0NkBpMl\BSG1UVw>?NWHkUoJCUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=MoXMNlM6OzB7OUS=
HCC827NFnKT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXu3NkBpM4HpNmlEPTB;MD6wNVIh|ryPMYKyN|k4OzF4OB?=
A549Ml7QT4lv[XOnIFHzd4F6NUTVZYpmOSEQvF2=M3P6TlEhcA>?M4rx[2ROW09?MVPJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN|k6KM7:TR?=NF\4PW0zOzl6OEO1OC=>
A549Ml[2SpVv[3Srb36gRZN{[Xl?MVmxJO69VQ>?MW[xJIg>MkH4SG1UVw>?M2HObmNmdGy3bHHyJJVxfGGtZR?=MlrqNlM6QDh|NUS=
HCC827NFTiUodMcW6jc3WgRZN{[Xl?MUewMlUh|ryPNH;KR5UzKGh?Mk[wSG1UVw>?MnnMTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?NXzzUHROOjN7OUOzNlg>
HCC827NUHn[ooxTnWwY4Tpc44hSXO|YYm=M4jUVlAvPSEQvF2=NX3lXItGOiCqNIe2Z|dFVVORNV;hNG93UW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=M{H4WVI{QTl|M{K4
HCC827MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfEe3AyOCEQvF2=MVG3NkBpM1PLfWROW09?NVPrUFhVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBo\W[rdHnubYIue2Wwc3n0bZZmKGi3bXHuJGhESzh{NzDj[YxteyCqYYLic5JqdmdiRVfGVkBGPzR4IITvJGE4PTBiZHXs[ZRqd25id3n0bEBKSzVyIH;mJFAvODB3OEGg{txONXHxdHFKOjRyNUO2O|Q>
A431MnrZT4lv[XOnIFHzd4F6MWSxNFAh|ryPMkHJN|AhdWmwNX3IRZcxUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIIPo[YQhdWWvYoLhcoUhfmW|aXPs[ZMhf2m2aDDJR|UxKG:oIEGuNUDPxE1?NGjENFYzPDB7NESzNi=>
BCRP-MDCK2MknjSpVv[3Srb36gRZN{[Xl?NYXlZotsOS56IN88US=>NYXhZ2hVPzJiaB?=MUfEUXNQMYnJcoNz\WG|ZTDv[kBxdGG|bXGgcYVu[nKjbnWg[ZhxemW|c3nvckBw\iCEQ2LQJIV5eHKnc4PpcochemWyb4L0[ZIh\2WwZTDHSnA>MVyyOFE5PDJzMx?=
BCRP-MDCK2MUPGeY5kfGmxbjDBd5NigQ>?M1\mN|EvQCEQvF2=NWnVNVVlPzJiaB?=NUPSbos{TE2VTx?=MX\S[YR2[3Srb36gc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZRM3X4VlI1OTh2MkGz
MDCKMliyR5l1d3SxeHnjJGF{e2G7MYC3NkBpM3nw[2ROW09?MWLHTVUxRTFwNEWg{txONUfuR2t[OjRzOESyNVM>
MDCK2MVXGeY5kfGmxbjDBd5NigQ>?NGWzVncyNjhizszNMVO3NkBpMYnEUXNQM4LFcmlvcGmkaYTpc44hd2ZiaIXtZY4hSkOUUDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMhUG:nY3jzeEA{OzN2MjDhZ4N2dXWuYYTpc44hf2m2aDDJR|UxKG:oIEOuNVkh|ryPMXSyOFE5PDJzMx?=
A431NVjNc21PS3m2b4TvfIlkKEG|c3H5MlTZO|IhcA>?MW\EUXNQNVnJVIs6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR|MTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR|UxKG:oIECuOVUh|ryPNXfFWHhmOjR2MUGxNlM>
Calu3M36xS2N6fG:2b4jpZ{BCe3OjeR?=MX:3NkBpMkTWSG1UVw>?M2TVN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNidHV|IHPlcIx{KGW6cILld5NqdmdiSFXSNkB4cXSqIFnDOVAhd2ZiMD65PUDPxE1?NGjySoEzPDRzMUGyNy=>
KBNHfNNY9McW6jc3WgRZN{[Xl?NVP3U29jOTBizszNNED4S3cyKGh?NFTOV2FFVVORNGnYWGpKdmirYnn0bY9vKG:oIFXHSk1{fGmvdXzheIVlKGG3dH;wbI9{eGixconsZZRqd25ib3[gSWdHWiC5aYToJGlEPTBib3[gNE4xOjVizszNNF;kVmozPDRzMUGyNy=>
BEAS2BMlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzoeGc2OCEQvF2=NYTXd5F4PzJiaB?=M1H1Z2ROW09?NELsbmpKSzVyPUGzMlk1KM7:TR?=MXGyOFYxPzV7MR?=
NCI-H1975NFXxW4ZHfW6ldHnvckBCe3OjeR?=NXTLTGxiOTByIN88US=>MoT2NVUxKG2rbh?=NIq0U2FFVVORNFjtUpRKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62NWK1[YFrOjR4MEe1PVE>
HelaNF7iTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVT4UFc{OjRiaB?=MUPEUXNQNEfkeoJKSzVyPUKuOlch|ryPNX7kdlZ1OjR5M{GyPFE>
HepG2NFqwfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1H1elI1KGh?NX\1fWJPTE2VTx?=NYDIXlBKUUN3ME22MlQzKM7:TR?=M2nBPFI1PzNzMkix
Sf9NFL4UnpMcW6jc3WgRZN{[Xl?M1faWFExKG2rbh?=MUXEUXNQM1qxfGlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCqaYOteIFo\2WmIFXHSnIhMGGvaX7vJIFkcWRiNkS1MVEyQDZrIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>MWiyOFc{OTJ6MR?=
SW620MlXtR5l1d3SxeHnjJGF{e2G7NIT6SZM1QCCqMYXEUXNQNX\sbY1yUUN3ME2yPE4zKM7:TR?=MYiyOFkxODV7NB?=
HCC827NIPZWm1HfW6ldHnvckBCe3OjeR?=M4XWe|AvPSEQvF2=NYnkR2F3OiCqMnTqSG1UVw>?MYPkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdg>?MlfINlM6QTN|Mki=
HCC827NI\QeHRHfW6ldHnvckBCe3OjeR?=Mnv6NE42KM7:TR?=MVmyJIg>MmS2SG1UVw>?MXnkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=MoHQNlM6QTN|Mki=
HCC827Ml3xR5l1d3SxeHnjJGF{e2G7NFHRW5ExNjVizszNMV[3NkBpNVzFWVZkTE2VTx?=NUfaNXFQcGG|IH7vJIN6fG:2b4jpZ4l1gQ>?MUmyN|k6OzN{OB?=
NCI-H1975NXm4dmpbTnWwY4Tpc44hSXO|YYm=MWCxNEDPxE1?NInqdFI5KGh?MVjEUXNQNX:1Z|dD\G:nczDuc5QhcW6qaXLpeIkhTUeIUjDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbh?=M4jndFI{OTF4MU[4
A431NXnWclVPU2mwYYPlJGF{e2G7MWCxJO69VQ>?M3\6b|EhcA>?MWDEUXNQMnWybIF{KG6xIHnydoV3\XK|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?NInT[HkzPDlyMEW5OC=>
LNCaPNHTLWGxHfW6ldHnvckBCe3OjeR?=MmP0NVAh|ryPNYeyeGt3Omhib4KgOEBpM1fneGROW09?MkjN[I9meyCwb4SgbY5pcWKrdDDheZRweGixc4Doc5J6dGG2aX;uJI9nKGmvbYXuc5B2emmoaXXkJIZt[WdvdHHn[4VlKEKveDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{OlCfQWTQNU\ONnlDOTh4NkezNVI>
H1975NYXjWGhzU2mwYYPlJGF{e2G7M4G5flEh|ryPMlzWNlQhcA>?MnH2SG1UVw>?NYTPTlk1\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?NHn1cnUzPDZyN{W5NS=>
H1975NHHQRY5HfW6ldHnvckBCe3OjeR?=MkDXNUDPxE1?NFXFb2IzPCCqM4r0[mROW09?NULFTVJl\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPNF;lU4EzPDZyN{W5NS=>
HCC827MkXHT4lv[XOnIFHzd4F6Mnr3NE4yOSEQvF2=M4XNd|EhcA>?MVrEUXNQNYTJZ3N2cGG|IH7vJIlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGVITlJiYYPz[ZN{\WRiYYOgdoVkd3[ncomgc4YhTUeIUjDheZRweGixc4Doc5J6dGG2aX;uM2KwWFI1OTJ2OEm4
H1975M1;tTGtqdmG|ZTDBd5NigQ>?MUCwMlM{KM7:TR?=NFvUOY4zKGh?M4D4[mROW09?NEjCS|Fld2W|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSUuWIIDoc5NxcG:{eXzheIlwdg>?M4\WTFI1OTJ2OEm4
H1975NULmU49VU2mwYYPlJGF{e2G7NIHuWHgxNjN|IN88US=>M{T6ZlIhcA>?NV;WVJBFTE2VTx?=Mkfr[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVTUyCyaH;zdIhwenmuYYTpc44>M3XFOlI1OTJ2OEm4
H1975M2Xrd2tqdmG|ZTDBd5NigQ>?MmDWNE4{OyEQvF2=MoX2NkBpM{jLeGROW09?MkH5[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;uNVuyVllFOjRzMkS4PVg>
H1975MYHLbY5ie2ViQYPzZZk>NEnheYExNjF{NTFOwG0>MlP1NlQhcA>?NXPGOXRCTE2VTx?=M4nPSYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?MofPNlI{Ozl|NEK=
H1975NIX2SlJMcW6jc3WgRZN{[Xl?MnHyNE42KM7:TR?=MXqyOEBpMnTHSG1UVw>?M4XFcYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=Mlq2NlI{Ozl|NEK=
H1975MVLLbY5ie2ViQYPzZZk>NFvQU3ExNjVizszNM1;FU|I1KGh?NIjyT5lFVVORMljR[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfC2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wNXnTTnRlOjJ|M{mzOFI>
MIAPaCa2NEnGZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHIdJUzNjVizszNNFXMcoM4OiCqMVHEUXNQNV7jWodtcGG|IH7vJIdzd3e2aDDpcohq[mm2aX;uM{DiTVIxPDZ4NUW1
MIAPaCa2NXH0SYRtS3m2b4TvfIlkKEG|c3H5M1nFZlEh|ryPNWLLVI03OTBiZB?=MYjEUXNQMluybIF{KG6xIHP5eI91d3irY3n0fUBie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBkd2yxbomg[o9zdWG2aX;uMlPWNlA1PjZ3NUW=
MIAPaCa2MmDCRZBweHSxc3nzJGF{e2G7MXKxNEDPxE1?NHPLXYQzPGhib4KgOFghcA>?NV\yfGwzTE2VTx?=M4DrbYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO=NIn5PHozODR4NkW1OS=>
MIAPaCa2Mm\nRZBweHSxc3nzJGF{e2G7NH3pV4czOCEQvF2=M{LoRVI1KGh?M3LTdmROW09?M2HZUoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMh[2G|cHHz[UA{KGGldHn2ZZRqd25?NHHzXm8zODR4NkW1OS=>
EoL-1MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rh[WlEPTB;NT6xO{BvVQ>?MVzTRW5ITVJ?
NCI-H720NFO1flhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXUcWZRUUN3ME2yOk46OiCwTR?=MmK1V2FPT0WU
NCI-SNU-5Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nvZmlEPTB;MkiuNVkhdk1?NE\sS4hUSU6JRWK=
EW-3Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLOTWM2OD12Nj6wOEBvVQ>?Mni5V2FPT0WU
HCC2218MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGr4UHBKSzVyPUWwMlU6KG6PMX7TRW5ITVJ?
HuO-3N1M1\sNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnr3TWM2OD13Nj6wPUBvVQ>?MmHiV2FPT0WU
DBM4Dmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\wTWM2OD14MD65OkBvVQ>?MYPTRW5ITVJ?
HSC-4NV7Fd4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jPc2lEPTB;NkGuOVMhdk1?M1TZSXNCVkeHUh?=
DOKNGLteoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\WZpR5UUN3ME25N{43OiCwTR?=M1Hx[HNCVkeHUh?=
H9Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HifmlEPTB;MUO3MlIhdk1?NX2xcFZIW0GQR1XS
NCI-H292MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjQVWhjUUN3ME2xOlIvPjZibl2=M2rJXHNCVkeHUh?=
HSC-2MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXITWM2OD1zNkWuOVchdk1?MXnTRW5ITVJ?
LU-65M4DXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2Hmc2lEPTB;MU[2MlYyKG6PNWLpO3V2W0GQR1XS
BV-173NHXPd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUj0dno4UUN3ME2xPFYvPTVibl2=NG[0N4tUSU6JRWK=
LB2241-RCCM{\aXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTF7ND65N{BvVQ>?MmHlV2FPT0WU
KG-1NWPvZVZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jUdGlEPTB;MkC0MlM1KG6PNVvN[pVMW0GQR1XS
CHL-1NXnZe4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\CTWM2OD1{MEiuOVEhdk1?M4LCZ3NCVkeHUh?=
KYSE-140MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XFS2lEPTB;MkC5Mlk3KG6PNGixZ5lUSU6JRWK=
DU-145MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEC4SpBKSzVyPUKxPU4xPCCwTR?=NFrVNoZUSU6JRWK=
EW-13MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7yTWM2OD1{MkWuNUBvVQ>?M3e0bnNCVkeHUh?=
KYSE-450M4XKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJ2Nz65NkBvVQ>?NGPMRZNUSU6JRWK=
CAL-72M3TXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmqzTWM2OD1{NkiuO|Mhdk1?NVP2WlI6W0GQR1XS
MEG-01NFOyc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DDfGlEPTB;Mke2Mlc3KG6PM4jRXnNCVkeHUh?=
HCE-TNX7TS4lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\ObWlEPTB;Mke5Mlc6KG6PM4m5VnNCVkeHUh?=
NCI-SNU-1M3;ab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjyeGNKSzVyPUK4N{4{OiCwTR?=MlPnV2FPT0WU
CAL-27MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vEV2lEPTB;Mki5MlA5KG6PMVrTRW5ITVJ?
BALL-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTxTWM2OD1{OUeuOFIhdk1?MUDTRW5ITVJ?
SBC-1NWDJW|FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzXS5VIUUN3ME2zNFcvPzlibl2=MlLBV2FPT0WU
CAL-54NWLpcYZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\VTWM2OD1|MUGuNlMhdk1?MofTV2FPT0WU
TI-73M3jmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTNzMj63OUBvVQ>?MmX1V2FPT0WU
P12-ICHIKAWANWPPb206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nWTGlEPTB;M{K4MlA3KG6PNFXmSVFUSU6JRWK=
ACHNM{S3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfucWVKSzVyPUOzNU41KG6PMX7TRW5ITVJ?
PC-14M2XHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jLPWlEPTB;M{OzMlQyKG6PMnLCV2FPT0WU
HCC1806M1TuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjucIxXUUN3ME2zN|cvPTFibl2=NFX3O5JUSU6JRWK=
SK-MEL-24MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfkc4xKSzVyPUOzO{45PyCwTR?=M1TB[XNCVkeHUh?=
A4-FukNFPte|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTN3MD6wNkBvVQ>?NFHYfnpUSU6JRWK=
ECC10NVPPOJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTN3Mj65OkBvVQ>?M1XmT3NCVkeHUh?=
KASUMI-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTN4Nj63N{BvVQ>?NXTZW5h4W0GQR1XS
CAL-33NHPEdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTN5MD65JI5OMlPXV2FPT0WU
MDA-MB-175-VIINH20fG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;OSHdvUUN3ME2zO|gvQDhibl2=NFjFcWhUSU6JRWK=
NUGC-3NHjaUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{Lv[WlEPTB;NECxMlgyKG6PMY\TRW5ITVJ?
KY821MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3tW29qUUN3ME20NFgvPTdibl2=MX3TRW5ITVJ?
CTB-1M2TiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmP3TWM2OD12MkSuOEBvVQ>?MYTTRW5ITVJ?
DoTc2-4510M{TpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYr3XHFsUUN3ME20OFIvOTJibl2=MoTsV2FPT0WU
EFO-27M33CU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTR3ND63OEBvVQ>?NXLZNWw1W0GQR1XS
BPH-1NHj3W3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTR7MT6xOkBvVQ>?NXHTVHdDW0GQR1XS
KYSE-270NV;lcppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTR7OD62OUBvVQ>?MULTRW5ITVJ?
HO-1-N-1NHzQdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzOTWM2OD13MEmuNlUhdk1?NXnGRlk2W0GQR1XS
SK-MEL-1M2mwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTp[4Z{UUN3ME21NVAvQTlibl2=MU\TRW5ITVJ?
MOLT-13NX;lb|IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rpemlEPTB;NUG0MlgzKG6PMkC2V2FPT0WU
TK10M2PudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzsfllKSzVyPUWxOU4yOSCwTR?=NEDjTG5USU6JRWK=
HNNYTabXl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTVzNz6zPEBvVQ>?MVfTRW5ITVJ?
SCC-15NW\Db4VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjvTWM2OD13MkWuOlghdk1?NUjWe|Y3W0GQR1XS
NCI-H358M3nUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjEXYlKSzVyPUWyO{43PiCwTR?=NFjkSmZUSU6JRWK=
KYSE-180NHzaT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mle4TWM2OD13M{CuOlIhdk1?M{XrdHNCVkeHUh?=
NCI-H82NHL3OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvIdYM5UUN3ME21OFAvPSCwTR?=NGXkS2VUSU6JRWK=
NB7NV7VVm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4f3U2lEPTB;NUS2MlMzKG6PNHTY[3JUSU6JRWK=
DSH1M4jGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTV4Nj64PEBvVQ>?Mk\3V2FPT0WU
RS4-11NGixTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13hb2lEPTB;NU[4MlU6KG6PNXK1ZW9kW0GQR1XS
CANNH[wd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TUc2lEPTB;NUiwMlc3KG6PNH\UdpNUSU6JRWK=
Ca9-22MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\3TmlEPTB;NUi4MlY1KG6PNW\JNJZLW0GQR1XS
CAL-39MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTV7Nj6zJI5OMnjzV2FPT0WU
NCI-H1623MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHHTWM2OD13OUmuN|Yhdk1?MYDTRW5ITVJ?
FADUMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVq3T3BzUUN3ME22NFQvPjlibl2=M{ezZXNCVkeHUh?=
NB69MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DTb2lEPTB;NkG0MlM2KG6PMV;TRW5ITVJ?
Ramos-2G6-4C10Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHlOHRKSzVyPU[yNU41PiCwTR?=NHLaV2pUSU6JRWK=
LB1047-RCCNHraWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTTW3R1UUN3ME22NlUvOjlibl2=MUjTRW5ITVJ?
MV-4-11NEPYVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17mWGlEPTB;NkK3Mlchdk1?MUPTRW5ITVJ?
DBTRG-05MGNFP1VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TuO2lEPTB;NkOyMlI5KG6PNF3KbphUSU6JRWK=
ME-180NF3kW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTZ|Mj65JI5OMlftV2FPT0WU
NBsusSRNUOxb4FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUC5eohRUUN3ME22OFYvPTJibl2=MVPTRW5ITVJ?
COR-L105M3PVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHNTWM2OD14NkKuOVMhdk1?NFHSeWVUSU6JRWK=
ETK-1M{XaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXoTWM2OD14NkKuOVkhdk1?MnvpV2FPT0WU
L-363NF;nSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXMN3E3UUN3ME22O|EvQTRibl2=NFzKPXNUSU6JRWK=
LU-134-ANGLMZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrvUYNKSzVyPUexPU4xQSCwTR?=MnfVV2FPT0WU
NCI-H1770MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDxTWM2OD15MkKuOEBvVQ>?M2DBWXNCVkeHUh?=
HAL-01Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{npW2lEPTB;N{O0MlcyKG6PMnTQV2FPT0WU
COLO-684NEnWOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTd3Mz6wNUBvVQ>?NHSwdmFUSU6JRWK=
TE-6MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlriTWM2OD15NkSuN|Ehdk1?MkHVV2FPT0WU
A431MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXiVYhSUUN3ME23PFAvODRibl2=NV\HUlV4W0GQR1XS
LU-135Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWf3R45qUUN3ME23PFMvODNibl2=NVPtTY5EW0GQR1XS
EC-GI-10NXTG[|JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\o[4xyUUN3ME23PFgvPTJibl2=MVzTRW5ITVJ?
TE-12NVXUT5FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTh{MT6xNUBvVQ>?M4HGWXNCVkeHUh?=
LoVoMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrJUoVKSzVyPUi1PU4xPiCwTR?=M2XwdnNCVkeHUh?=
23132-87NHO2e|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\zN2lEPTB;OE[0MlI5KG6PMm[5V2FPT0WU
AU565NGf3OphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDtfINKSzVyPUi2PU43KG6PNWnX[WI2W0GQR1XS
DELM3LyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTocIdnUUN3ME24O|cvPjVibl2=NWjWW3Y2W0GQR1XS
COR-L88NW\BO494T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGn3eHhKSzVyPUi4Nk4zPiCwTR?=NYXrVphRW0GQR1XS
NCI-H2126NHPmXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTh6Mj64N{BvVQ>?NUX1e|NTW0GQR1XS
CAPAN-1M4e1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDoRWJKSzVyPUi4N{4zQSCwTR?=M1;MenNCVkeHUh?=
BT-474NWL5OIVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrBfY1UUUN3ME25N|gvOTRibl2=MlvKV2FPT0WU
BHYM4jCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLnR211UUN3ME25O|UvPDhibl2=M1jUeXNCVkeHUh?=
HT-3NHG5S|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTl6Mj60NUBvVQ>?NYDIdmNMW0GQR1XS
SK-NEP-1NFvY[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTl6OT60OEBvVQ>?NGPRdm1USU6JRWK=
MS-1NHPsfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDvTWM2OD17OUSuOlkhdk1?Mle0V2FPT0WU
DOHH-2M4XxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPORnNMUUN3ME2xMlAxODJzIN88US=>NHnYdYFUSU6JRWK=
NCI-H1304MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFwMEG2OFMh|ryPMlLUV2FPT0WU
EM-2M2\6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTlV|c3UUN3ME2xMlA{ODF4IN88US=>MlnmV2FPT0WU
MHH-PREB-1NVrtO4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ribGlEPTB;MT6wPFQ2OSEQvF2=NWDqNlkxW0GQR1XS
KU-19-19Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInqVGxKSzVyPUGuNFg2PDFizszNM2P1fXNCVkeHUh?=
NCI-H1648MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4P2TmlEPTB;MT6xNFYyPiEQvF2=NGHOPWhUSU6JRWK=
MKN1NEi0dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{ez[GlEPTB;MT6yNVk5PyEQvF2=MXjTRW5ITVJ?
SNU-449M3vwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDJdoZ[UUN3ME2xMlIzOjB6IN88US=>NIfSb2FUSU6JRWK=
OAW-42NFLCdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmr2TWM2OD1zLkK3PFI2KM7:TR?=NVTk[ld7W0GQR1XS
769-PMn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPpV4lKSzVyPUGuNlc6OThizszNMorOV2FPT0WU
SW1088NWnYWpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXtTWM2OD1zLkK5OlA4KM7:TR?=M1\EWHNCVkeHUh?=
GCIYNYfFdJdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{OwOWlEPTB;MT6zNFE{OiEQvF2=NVOzUnhzW0GQR1XS
CTV-1NYPFVlR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;zc41wUUN3ME2xMlMxQCEQvF2=M4HzZ3NCVkeHUh?=
NCI-H1092MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4D4SWlEPTB;MT6zNFg2KM7:TR?=NV3lOXQ1W0GQR1XS
NKM-1MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTFwM{K1PVch|ryPMl\SV2FPT0WU
NCI-H1650M4TWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HmdmlEPTB;MT6zN|Q5OiEQvF2=MoDaV2FPT0WU
SW954MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFwM{SwOFgh|ryPNYfYco9jW0GQR1XS
SW48M{XoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTFwM{[2NVgh|ryPNXXRNGE4W0GQR1XS
SK-N-DZMkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUe3R2lKUUN3ME2xMlM3QTR5IN88US=>Ml[3V2FPT0WU
KMOE-2MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXUTWM2OD1zLkO5PFE2KM7:TR?=MV7TRW5ITVJ?
NB5NUfRZm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXKVXBKSzVyPUGuOFA5QTRizszNMlToV2FPT0WU
CCRF-CEMMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILiSG9KSzVyPUGuOFEyOSEQvF2=Ml\BV2FPT0WU
RH-1NVvMOXBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jhRWlEPTB;MT60NVE{PiEQvF2=MXTTRW5ITVJ?
NCI-H526M4rBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPvdol1UUN3ME2xMlQ{QDJ4IN88US=>MXfTRW5ITVJ?
697NV;ZZYx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjle|hKSzVyPUGuOFQyODRizszNNXLhW21NW0GQR1XS
J82NXPRcY1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jEU2lEPTB;MT60OVc3PiEQvF2=M3PadHNCVkeHUh?=
BE-13MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\MUmlEPTB;MT61NFY4OSEQvF2=NHHFeWVUSU6JRWK=
SASMlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;XZWlEPTB;MT61NVYzOiEQvF2=MXHTRW5ITVJ?
SCC-25NYPFcJhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXIV5llUUN3ME2xMlUzOzJ{IN88US=>Mk[zV2FPT0WU
LAMA-84NEW4dm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37sc2lEPTB;MT61N|gyPSEQvF2=Mo\DV2FPT0WU
HSC-3MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIm3NGxKSzVyPUGuOVQ{QCEQvF2=NYjLUJFuW0GQR1XS
BT-549NHXtTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDpOpVKSzVyPUGuOVg4PDdizszNNXrZNZFJW0GQR1XS
ML-2M37HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHKT4FKSzVyPUGuOlQxOjlizszNMmfEV2FPT0WU
BB30-HNCMlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHH3[GxKSzVyPUGuOlg6PzJizszNMk\DV2FPT0WU
PANC-03-27NFeyUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTFwN{CxN|kh|ryPNH6xVJVUSU6JRWK=
COLO-678Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1GzSGlEPTB;MT63N|Q1PCEQvF2=MlizV2FPT0WU
NCI-H1666NXq5SWw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGr0eYFKSzVyPUGuO|Q4ODRizszNMWLTRW5ITVJ?
NCI-H209MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTFwN{eyOlkh|ryPMn\TV2FPT0WU
EPLC-272HNVXy[JdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4D0WWlEPTB;MT64OVU1QSEQvF2=M3XjdHNCVkeHUh?=
OMC-1NEC0ZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXT1SoZlUUN3ME2xMlk6QDh6IN88US=>NXPMUHlwW0GQR1XS
HCC70MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmm4TWM2OD1{LkCwPFE2KM7:TR?=Ml;QV2FPT0WU
CAL-12TMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLZTWM2OD1{LkCxPFYyKM7:TR?=NUX6OotyW0GQR1XS
TGBC24TKBM{jqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTJwMEK5OlEh|ryPMV\TRW5ITVJ?
EKVXNFrwOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfEZ3ZtUUN3ME2yMlA1QTN7IN88US=>MVrTRW5ITVJ?
SW1116M{Pyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{joNmlEPTB;Mj6wOlAxQSEQvF2=Mo\wV2FPT0WU
NCI-H2009NG\WfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXftT|lqUUN3ME2yMlA3OjF2IN88US=>NFj0e5lUSU6JRWK=
RPMI-8866MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV65UYpiUUN3ME2yMlA5PDhzIN88US=>MXvTRW5ITVJ?
KARPAS-45NYf5TZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3H4R2lEPTB;Mj6xNlQ4QSEQvF2=MnHWV2FPT0WU
RXF393NHnGXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LwU2lEPTB;Mj6xN|A{PiEQvF2=NXjaW3VpW0GQR1XS
786-0M4TSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXP3TFljUUN3ME2yMlE5PDB4IN88US=>MYnTRW5ITVJ?
SCC-4M1iwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJwMkG3O|Yh|ryPMnK5V2FPT0WU
BT-20NXOzdo0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonSTWM2OD1{LkK2O|Q1KM7:TR?=MX3TRW5ITVJ?
A498NFHi[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTJwMkm0NVUh|ryPMUnTRW5ITVJ?
IGROV-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzETWM2OD1{LkOxNlM4KM7:TR?=MV7TRW5ITVJ?
JVM-3MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33UTmlEPTB;Mj6zOFY1OyEQvF2=M4fBV3NCVkeHUh?=
NCI-H2170Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXDXFdTUUN3ME2yMlM1Pzh|IN88US=>NH;LOINUSU6JRWK=
EW-18M2TyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDIS4t7UUN3ME2yMlM2PDdzIN88US=>MljhV2FPT0WU
KU812NELXSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPnTWM2OD1{LkO2O|c6KM7:TR?=M{LtPHNCVkeHUh?=
NYNXPnd2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfrTWM2OD1{LkO3Nlch|ryPMoi0V2FPT0WU
HTC-C3NIXXZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHiTGk{UUN3ME2yMlQzOjZ5IN88US=>M{\OT3NCVkeHUh?=
CFPAC-1MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HlbWlEPTB;Mj60N|g3PCEQvF2=NIT6PVFUSU6JRWK=
HHM2PXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXRTWM2OD1{LkS5PFU1KM7:TR?=NGTlcopUSU6JRWK=
MKN7M4mx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;jXZdKSzVyPUKuOlI4PDhizszNMYjTRW5ITVJ?
TE-8MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTGdnZKSzVyPUKuOlM3PTNizszNNVr4[4ZKW0GQR1XS
MC-IXCM4f1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTOTWM2OD1{Lk[0OFU{KM7:TR?=NHq5UVZUSU6JRWK=
DMS-79MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjDUlNKSzVyPUKuOlkzQDRizszNM17tVXNCVkeHUh?=
Detroit562M3npV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfid5d7UUN3ME2yMlY6QDR3IN88US=>MoSxV2FPT0WU
HuP-T4NHjQfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnryTWM2OD1{LkeyPFE5KM7:TR?=NXL5dXpqW0GQR1XS
QIMR-WILNWSyWlh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rnXmlEPTB;Mj63OVk2OiEQvF2=M1PUV3NCVkeHUh?=
BB65-RCCM{nPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDXdZNRUUN3ME2yMlgxPzF|IN88US=>M2DxSXNCVkeHUh?=
PC-3NVLzcWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEf0boFKSzVyPUKuPFM{OTdizszNM2PYbnNCVkeHUh?=
OVCAR-3MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTJwOEW1PVQh|ryPM{\t[HNCVkeHUh?=
KYSE-510MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTJwOE[3PFYh|ryPNXu2ZW9nW0GQR1XS
HC-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{WxUGlEPTB;Mj65OFAyOiEQvF2=NHHPN|NUSU6JRWK=
NCI-H1693M4TXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3ZbmliUUN3ME2yMlk2QDl5IN88US=>NG[wfoJUSU6JRWK=
DU-4475MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTJwOUmwOVIh|ryPM2DuVHNCVkeHUh?=
COLO-680NMmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIG0Zm1KSzVyPUOuNFA1QTVizszNMYTTRW5ITVJ?
MN-60MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHHbm0xUUN3ME2zMlA1QTd2IN88US=>NIrreXVUSU6JRWK=
BCPAPMmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDaTWM2OD1|LkC4Nlk2KM7:TR?=NX7UU3hSW0GQR1XS
647-VNUj5PXNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWf0OJMzUUN3ME2zMlE3OjJizszNMn;BV2FPT0WU
HT-1376MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTNwMkC1NFYh|ryPMoLsV2FPT0WU
NCI-H1793NYriRXRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPoSnN5UUN3ME2zMlIyODl6IN88US=>MlHzV2FPT0WU
SW1463M3HlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDIdppKSzVyPUOuNlYyQTJizszNM{TGPXNCVkeHUh?=
NCI-H727NWi1ZXB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTNwM{i1PFQh|ryPNGTDeYlUSU6JRWK=
LB771-HNCNW\iRYh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTNwM{mxNlYh|ryPMYrTRW5ITVJ?
D-542MGMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTNwNESyNlIh|ryPMnnsV2FPT0WU
NTERA-S-cl-D1NHTvSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTNwNES5OVch|ryPMnvZV2FPT0WU
C8166NEfpVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTNwNE[1NlEh|ryPM3fydnNCVkeHUh?=
639-VNGGxS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7FRYRKSzVyPUOuOVc4QTJizszNM{G5d3NCVkeHUh?=
TE-1M2nmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTtcZNNUUN3ME2zMlU6OTZ7IN88US=>NImyVoRUSU6JRWK=
OAW-28NV\ue29kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTNwNUm0NlYh|ryPNWnlbZJOW0GQR1XS
SK-LU-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTNwNkC2OFUh|ryPMVnTRW5ITVJ?
CaR-1M1vZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjYO2dKSzVyPUOuOlExPDhizszNM1T4V3NCVkeHUh?=
A2780Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXX1dXBkUUN3ME2zMlY1ODh7IN88US=>MVvTRW5ITVJ?
C2BBe1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG4TWM2OD1|Lk[0OFA4KM7:TR?=MmrKV2FPT0WU
SK-MES-1NHnCfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jveWlEPTB;Mz62OFYyPCEQvF2=MUHTRW5ITVJ?
PANC-10-05NXSyWG5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rZcWlEPTB;Mz63NlA4OiEQvF2=NX7vSIRIW0GQR1XS
J-RT3-T3-5M4m5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;ySFVKSzVyPUOuO|U1ODZizszNNXTyenBOW0GQR1XS
ES4MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjqRW01UUN3ME2zMlgzOjh4IN88US=>M{P3fHNCVkeHUh?=
NCI-H28NVnhfng4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTNwOEK5OlEh|ryPMYTTRW5ITVJ?
NCI-H1155MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3BUIk5UUN3ME2zMlg1OTV7IN88US=>MXLTRW5ITVJ?
KURAMOCHIMkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1[xWGlEPTB;Mz64OlA2PiEQvF2=MVHTRW5ITVJ?
NCI-H69M1mzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mor2TWM2OD1|LkmwNVc5KM7:TR?=NF;XSYZUSU6JRWK=
IST-MES1NUjIUZR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PDOmlEPTB;Mz65OFAzQSEQvF2=MmP2V2FPT0WU
NH-12Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXWwS5RGUUN3ME2zMlk1OTh5IN88US=>MnTtV2FPT0WU
JVM-2M33MVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzEfXdKSzVyPUOuPVQ4PTJizszNM33yRnNCVkeHUh?=
EW-16MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nJUmlEPTB;Mz65OVU4PyEQvF2=MX7TRW5ITVJ?
NCI-H441NUe0PHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXRR|dKSzVyPUOuPVcxOTRizszNNV2yd45MW0GQR1XS
RCC10RGBMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\PNm9KSzVyPUSuNFEzPDZizszNNH\tb2JUSU6JRWK=
TCCSUPNFTURZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmD6TWM2OD12LkGxNFUh|ryPNFjLd2FUSU6JRWK=
HL-60M4DCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPwd3prUUN3ME20MlEzOjRzIN88US=>M{XMbXNCVkeHUh?=
EW-11MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTC[mV6UUN3ME20MlE{OjZzIN88US=>MlnsV2FPT0WU
KARPAS-299NV3UfYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHLTWM2OD12LkOxNFE{KM7:TR?=M{HYUnNCVkeHUh?=
SNU-C2BMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEWxcoVKSzVyPUSuN|Q3QDZizszNNGPRfVZUSU6JRWK=
LU-139M3[5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzCOlRKSzVyPUSuN|czPDdizszNMWnTRW5ITVJ?
HCC1937M17GVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjsTWM2OD12LkO3PVk{KM7:TR?=MVvTRW5ITVJ?
GR-STM1XxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTRwNEOxPEDPxE1?MnXIV2FPT0WU
SK-OV-3M1HtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrodIRKSzVyPUSuOFYxPDJizszNM4j6VnNCVkeHUh?=
A172MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTRwNUW1NlEh|ryPMX\TRW5ITVJ?
NB10M1zyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTRwNUm3PFEh|ryPNYLhSJluW0GQR1XS
P30-OHKNWLyR29tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmX2TWM2OD12LkixPVI6KM7:TR?=NHjiSGdUSU6JRWK=
KYSE-520MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTRwOEiwNVgh|ryPM2PTS3NCVkeHUh?=
KNS-62M13Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHFTWM2OD12LkmwPFA4KM7:TR?=MoLVV2FPT0WU
ES1MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGO3PFdKSzVyPUSuPVYxOzVizszNNEXRTG5USU6JRWK=
KOSC-2NUHOOnFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonZTWM2OD12Lkm5PVU6KM7:TR?=MYHTRW5ITVJ?
TE-9NXH6eGJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTVwMEG1NlUh|ryPNFzVR4NUSU6JRWK=
NCI-H1838MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLyco5KSzVyPUWuNFIxPzZizszNM1SwXXNCVkeHUh?=
KP-N-YNMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2P2e2lEPTB;NT6xNlU6OSEQvF2=MnTVV2FPT0WU
ALL-PONGrPTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTVwMkK1PFch|ryPM2HaXnNCVkeHUh?=
NOMO-1M2PCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nPTmlEPTB;NT6yN|E4PiEQvF2=Mn3zV2FPT0WU
CGTH-W-1NXLHOGNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGmyWnFKSzVyPUWuN|g2QDRizszNM3rPUnNCVkeHUh?=
ATN-1MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjZbXNKSzVyPUWuOFEyQDRizszNNFex[2RUSU6JRWK=
AGSM3vYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYq5OZJiUUN3ME21MlQ6PjF6IN88US=>MWfTRW5ITVJ?
SW13M1;FXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rid2lEPTB;NT61N|I3PSEQvF2=MU\TRW5ITVJ?
SW1990NFL4PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPHd|lKSzVyPUWuOlIzQDVizszNMlTBV2FPT0WU
BFTC-905MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHy3SGlKSzVyPUWuOlU5PzhizszNMkPNV2FPT0WU
RMG-INXzRVWw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;UTWM2OD13Lk[1PVQzKM7:TR?=NYDhdpQ{W0GQR1XS
HD-MY-ZMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;ycmlEPTB;NT62PFU5OSEQvF2=MmPDV2FPT0WU
HCC1187MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnpTWM2OD13LkexNFMzKM7:TR?=MYXTRW5ITVJ?
HCC2998M4DSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\zTWM2OD13LkexPFc4KM7:TR?=M4roVHNCVkeHUh?=
RT-112MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\zbVNKSzVyPUWuPVAzPDVizszNMkPDV2FPT0WU
CAKI-1MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nxemlEPTB;Nj6wNFk5PSEQvF2=MXrTRW5ITVJ?
HDLM-2MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTKTWM2OD14LkCxOFg6KM7:TR?=MXPTRW5ITVJ?
TE-10NHz0XWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Hq[GlEPTB;Nj6wOFg{OyEQvF2=NUDQRmxCW0GQR1XS
KE-37NF;TPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnwWGJlUUN3ME22MlA4OjV6IN88US=>MkXpV2FPT0WU
RCM-1MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTZwMEe3NVkh|ryPM3;zcXNCVkeHUh?=
MewoMk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\tZ4lHUUN3ME22MlEyPDh5IN88US=>MmnmV2FPT0WU
L-428Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTZwMUiwN|ch|ryPM1vTVnNCVkeHUh?=
8-MG-BANFXhU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HyTmlEPTB;Nj6xPVM4QSEQvF2=NEjn[GlUSU6JRWK=
SK-MEL-28MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVSxXmtiUUN3ME22MlIxQTZ5IN88US=>M4DXUnNCVkeHUh?=
VA-ES-BJM1WzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{WwcmlEPTB;Nj6zNFQ3OiEQvF2=MYXTRW5ITVJ?
CAL-120NIHEcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17yOmlEPTB;Nj60OVE3OiEQvF2=MlWzV2FPT0WU
GAMGM1XQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTZwNUC2NkDPxE1?MWjTRW5ITVJ?
MSTO-221HMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jkZWlEPTB;Nj61NVE4KM7:TR?=M{PVbHNCVkeHUh?=
GCTNILDTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDCb5FHUUN3ME22MlU{Ozh5IN88US=>NILnO3ZUSU6JRWK=
SH-4MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\rNmlEPTB;Nj61PFg1PCEQvF2=Mn\jV2FPT0WU
Calu-3MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfxTWM2OD14Lk[1OVY5KM7:TR?=NULjXoN1W0GQR1XS
SK-HEP-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3HTWM2OD14LkexO|U{KM7:TR?=M{f1U3NCVkeHUh?=
PFSK-1NGOxTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17XXmlEPTB;Nj63N|Q4QCEQvF2=MWjTRW5ITVJ?
NB12NXTlNI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXHUYVKSzVyPU[uO|g1ODRizszNMYDTRW5ITVJ?
A388MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXMUJVKSzVyPU[uPFk2OiEQvF2=NX;rVIoyW0GQR1XS
KLENETsOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfR[I13UUN3ME22Mlk3PTF4IN88US=>NXz3[VIzW0GQR1XS
TE-11NGDSZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfmW3l{UUN3ME23MlA1QTZ5IN88US=>M2XBNHNCVkeHUh?=
NCI-H2405MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\Jdm5pUUN3ME23MlA5Ozl|IN88US=>NHLOZ|NUSU6JRWK=
OVCAR-4MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjhbng3UUN3ME23MlE2OzVizszNMoTQV2FPT0WU
KP-N-YSMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mof4TWM2OD15LkG4NVQh|ryPMoPlV2FPT0WU
NOS-1M1POTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{D0WGlEPTB;Nz6yOVgzQCEQvF2=MoXCV2FPT0WU
DMS-114M3LsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTdwMkm2N|Eh|ryPNH\0U5VUSU6JRWK=
NCI-H2030Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\UfXRXUUN3ME23MlM{Pjl6IN88US=>MVrTRW5ITVJ?
HELNVPaPZlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTdwM{e1NlEh|ryPNEnzVWtUSU6JRWK=
CAL-62NI\2[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTdwM{m4OlYh|ryPMW\TRW5ITVJ?
COLO-668MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTdwNEO5Olch|ryPNV\S[JFQW0GQR1XS
SKG-IIIaNFK1[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYWx[48zUUN3ME23MlQ2OzhzIN88US=>NF;FWnRUSU6JRWK=
HCC1419M2S5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLRd3B7UUN3ME23MlQ3QDN|IN88US=>NGHQWIpUSU6JRWK=
OS-RC-2NH34UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3OTot[UUN3ME23MlQ6QDl2IN88US=>MU\TRW5ITVJ?
COLO-829MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\0d2lEPTB;Nz62OlQ3OyEQvF2=NE\NcIhUSU6JRWK=
NB13NX76OJN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\YTWM2OD15LkiyOlY4KM7:TR?=MVrTRW5ITVJ?
DK-MGNH[0No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHJPXQxUUN3ME23Mlg{OjBzIN88US=>NFLwbo1USU6JRWK=
SHP-77MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHhVlRPUUN3ME23Mlg3PjV|IN88US=>NXnDfoJzW0GQR1XS
NCI-H661MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRThwMEW4Olch|ryPM2nQVHNCVkeHUh?=
AM-38M2TlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrBTXNKSzVyPUiuNVYzQCEQvF2=NH\UcoRUSU6JRWK=
VM-CUB-1NYnBTW42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXqcVBQUUN3ME24MlE4ODJ7IN88US=>MnjQV2FPT0WU
KYSE-70M4rBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRThwMUm3OlEh|ryPMnnJV2FPT0WU
5637NG[2dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIf2bmRKSzVyPUiuN|ExPTVizszNMl;FV2FPT0WU
TGBC11TKBMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIO0NnVKSzVyPUiuOFYyPjRizszNMULTRW5ITVJ?
EGI-1MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLLTWM2OD16Lk[wNFg5KM7:TR?=NYro[XNSW0GQR1XS
D-392MGM4TTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRThwNk[yNVQh|ryPMUPTRW5ITVJ?
A673MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfHTWM2OD16Lk[3OlEyKM7:TR?=M2Drb3NCVkeHUh?=
COLO-792Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXLTWM2OD16Lke0PVQ3KM7:TR?=MnP0V2FPT0WU
NCI-H1792NHTwcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPNNopKSzVyPUiuPFg6ODNizszNNFzpTZVUSU6JRWK=
LS-1034NVfPOJRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzs[G1KSzVyPUiuPVQ3PTJizszNNFfF[XFUSU6JRWK=
D-566MGNIfQPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVP2c5lKUUN3ME25MlAyQDFizszNMoTLV2FPT0WU
NCI-H226NVHzO|l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPaXY1EUUN3ME25MlA6KM7:TR?=NHHNdplUSU6JRWK=
ChaGo-K-1NVTpdWJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHBWZV7UUN3ME25MlExPTd7IN88US=>MXrTRW5ITVJ?
NCI-H2228NGWxSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzwRVh1UUN3ME25MlEyODhzIN88US=>MV3TRW5ITVJ?
RPMI-8226NVXtd3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HT[mlEPTB;OT6xNVMxPCEQvF2=MWPTRW5ITVJ?
BFTC-909NFvtWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDLW2hKSzVyPUmuNVgzQTdizszNNWfrPWM4W0GQR1XS
HPAF-IIMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTlwMkK1NVgh|ryPM17PT3NCVkeHUh?=
Capan-2M{jCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGL6bYxKSzVyPUmuOFAyODlizszNMkfUV2FPT0WU
IA-LMMmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXn4WYx{UUN3ME25MlQyQTZ4IN88US=>M1:3VHNCVkeHUh?=
KP-4MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTlwNEi4N|gh|ryPM364SHNCVkeHUh?=
A101DMl\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTlwNUG3NVkh|ryPMo[1V2FPT0WU
EFO-21NIjE[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\YSGlEPTB;OT61PFc{PSEQvF2=MlrpV2FPT0WU
C32NVG3XngyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTlwNkOzOEDPxE1?NXO5U4xtW0GQR1XS
SW837NIH6Uo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTlwOES4NkDPxE1?MkG0V2FPT0WU
OCI-AML2M3v5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnBXnpMUUN3ME25Mlg3QTZizszNMnjsV2FPT0WU
NCI-H1355MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTlwOUSwPFgh|ryPMnP2V2FPT0WU
NCI-H2342NHLWVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvSZVZ2UUN3ME2xNE4xOTV3IN88US=>M1\wOnNCVkeHUh?=
A204NYOwN2tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTFyLkC0OlYh|ryPM2W1NnNCVkeHUh?=
CAL-51M3q1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfyTWM2OD1zMD6wPFc4KM7:TR?=MWjTRW5ITVJ?
HCE-4MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3vTWM2OD1zMD6xNVIzKM7:TR?=MX7TRW5ITVJ?
NCI-H810NH[2fGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfvXlVKSzVyPUGwMlE2QTdizszNMlvUV2FPT0WU
DJM-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLFe4dJUUN3ME2xNE4yPzN{IN88US=>NUPhTnpwW0GQR1XS
SK-UT-1NFPsdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvGTWM2OD1zMD6yOVc1KM7:TR?=NHHEdVNUSU6JRWK=
U031M{nvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nO[2lEPTB;MUCuNlY5PiEQvF2=M4P2UHNCVkeHUh?=
YH-13M4PPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPoSY5KSzVyPUGwMlMxPTdizszNNXfhXnNSW0GQR1XS
K5MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4n2T2lEPTB;MUCuN|M6PSEQvF2=NHntd5RUSU6JRWK=
HEC-1Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DicWlEPTB;MUCuOFA5OSEQvF2=NIP2WohUSU6JRWK=
A2058NEHifWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYX6[Jd1UUN3ME2xNE42PDlzIN88US=>MVfTRW5ITVJ?
SW962NWXWbIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13Nd2lEPTB;MUCuOlIxPCEQvF2=MWjTRW5ITVJ?
VMRC-RCZNV23elRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTVPIVbUUN3ME2xNE43PzR7IN88US=>MXLTRW5ITVJ?
D-336MGNFHL[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorWTWM2OD1zMD63NFA2KM7:TR?=M2rPbHNCVkeHUh?=
LXF-289NFfVNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTFyLke5Olch|ryPMoDFV2FPT0WU
SW900NEPOUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\NVGlEPTB;MUCuPFIzQCEQvF2=MYTTRW5ITVJ?
K-562MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;xUmlEPTB;MUCuPFM6PSEQvF2=NUnXSYxSW0GQR1XS
HCC38MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\iemdKSzVyPUGwMlk4OTZizszNMVjTRW5ITVJ?
SF-295NG\hZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXGyVJZZUUN3ME2xNE46QTB{IN88US=>M2ryOHNCVkeHUh?=
LB831-BLCNXTONFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DsNmlEPTB;MUGuNlU2PiEQvF2=MWDTRW5ITVJ?
FTC-133MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvIb4dKSzVyPUGxMlMxQDFizszNM3XFd3NCVkeHUh?=
HCC1954NYHmNpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTFzLkSzOkDPxE1?M{XKOHNCVkeHUh?=
GOTOMoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFzLkWyNFYh|ryPMmfOV2FPT0WU
LS-411NMnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTFzLk[xNFEh|ryPMWHTRW5ITVJ?
RPMI-7951NEDFW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;udVZuUUN3ME2xNU43OzR6IN88US=>MXXTRW5ITVJ?
NCI-H1299NV3ZWHd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHaTWM2OD1zMT62OlQ4KM7:TR?=NWnJSppCW0GQR1XS
MLMANU\GRmhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzYeVRKSzVyPUGxMlY6QTdizszNM4fYOnNCVkeHUh?=
MMAC-SFNUHLbI57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvaRmpKSzVyPUGxMlczPTJizszNNHnD[FhUSU6JRWK=
UM-UC-3NGrMd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkS0TWM2OD1zMT63OFIyKM7:TR?=MV3TRW5ITVJ?
SCC-9M{Sxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrrdpJIUUN3ME2xNU45OTVzIN88US=>MUTTRW5ITVJ?
HOSM1rB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfETWM2OD1zMT64Olg{KM7:TR?=NFXmPWNUSU6JRWK=
OE19NGD3SXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHLPGZKSzVyPUGxMlk{PjdizszNNUDLbG96W0GQR1XS
Mo-TMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFzLkm1OFEh|ryPMUTTRW5ITVJ?
CAMA-1NUDRR5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ftZ2lEPTB;MUKuNVY{OyEQvF2=NHLhR3NUSU6JRWK=
U-118-MGMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWftfYFNUUN3ME2xNk4zPDRzIN88US=>NUjibWNrW0GQR1XS
KS-1NWDTU3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3DNG9FUUN3ME2xNk4zQDN{IN88US=>M1fjfHNCVkeHUh?=
JARMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnmOG5LUUN3ME2xNk4{OzZ7IN88US=>MlH0V2FPT0WU
ABC-1NYDLTnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vwdWlEPTB;MUKuN|QyKM7:TR?=MXnTRW5ITVJ?
DaoyMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrCfopKSzVyPUGyMlQ2PDJizszNM1GyZnNCVkeHUh?=
C3ANGL5[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTF{LkW3PFUh|ryPMlTVV2FPT0WU
GT3TKBMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LZdWlEPTB;MUKuOlMzPyEQvF2=M{ewb3NCVkeHUh?=
DMS-273M1f0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTPTWM2OD1zMj64OlM{KM7:TR?=NX\GVItZW0GQR1XS
G-361NX[2SGd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HYU2lEPTB;MUKuPVEzQSEQvF2=M1TNfXNCVkeHUh?=
RH-18MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTF|LkK5OlIh|ryPNGXrfW1USU6JRWK=
SN12CMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HXZWlEPTB;MUOuN|gxQCEQvF2=M1HNVXNCVkeHUh?=
NCI-H1993NHr1WmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\LdI9KSzVyPUGzMlQzQDVizszNMoLLV2FPT0WU
LOXIMVINUm1dIRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PTTWlEPTB;MUOuOlE2OSEQvF2=M4rXe3NCVkeHUh?=
SK-PN-DWMmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrLS2hyUUN3ME2xN{45PDJ5IN88US=>NYHVflVqW0GQR1XS
KALS-1MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTF|Lki1NlUh|ryPMmXMV2FPT0WU
LAN-6NVHFe5ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XHb2lEPTB;MUSuNlU{KM7:TR?=NX7VT5RuW0GQR1XS
A549NEfY[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33nemlEPTB;MUSuOFcyOiEQvF2=NX;EbGxpW0GQR1XS
RDNFXpRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTCWJo4UUN3ME2xOE41QDF|IN88US=>NVTnTHdtW0GQR1XS
TGBC1TKBNV;re4p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTF2Lk[2NVUh|ryPMVrTRW5ITVJ?
NCI-H630MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTYdG9KSzVyPUG0Mlk1PjdizszNMkjRV2FPT0WU
MIA-PaCa-2M3HMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTF2Lkm2PUDPxE1?MmX1V2FPT0WU
NCI-H1755MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7ZTWM2OD1zND65PVU{KM7:TR?=MlH0V2FPT0WU
MOLT-4M1S4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF3LkC0PVch|ryPMmLtV2FPT0WU
CW-2M{jlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LpRWlEPTB;MUWuNVQzOSEQvF2=NVXjbJpRW0GQR1XS
COLO-320-HSRNHTXR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTF3LkWzNFch|ryPMWfTRW5ITVJ?
UMC-11NGnhNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTF3Lke1NlMh|ryPNXfDVlc6W0GQR1XS
MCF7MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zvT2lEPTB;MUWuPFE1PSEQvF2=NVPz[21KW0GQR1XS
NCI-H23M3H2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrCcWRKSzVyPUG1Mlg1OzhizszNMorGV2FPT0WU
HuCCT1NU\YOZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TmN2lEPTB;MUWuPFc1KM7:TR?=NXHCSmZPW0GQR1XS
MPP-89MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1n6fWlEPTB;MUWuPVQyPyEQvF2=Mnf4V2FPT0WU
HT55NGjnN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDHTWM2OD1zNT65OFc5KM7:TR?=M3Lod3NCVkeHUh?=
no-11NVPJblJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPydINKUUN3ME2xOU46PjZ|IN88US=>MYLTRW5ITVJ?
GP5dMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XINWlEPTB;MU[uNlE5PyEQvF2=M{LqcnNCVkeHUh?=
BHT-101MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\PR2lEPTB;MU[uNlQ{QSEQvF2=NEPSSYZUSU6JRWK=
M059JNW[2PJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfpXmFiUUN3ME2xOk4zQDRizszNMYfTRW5ITVJ?
D-283MEDNXv4WG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TBbGlEPTB;MU[uOFIxQSEQvF2=NGeyeWRUSU6JRWK=
BENNEfpVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH6wWXBKSzVyPUG2MlUyPTVizszNMlrVV2FPT0WU
LB373-MEL-DNVX1WWtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjobJVDUUN3ME2xOk44OjN{IN88US=>M{m3[XNCVkeHUh?=
MEL-HOMlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4j4PWlEPTB;MU[uPFg2PCEQvF2=M37NZXNCVkeHUh?=
GI-ME-NM2Dvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvnWlNnUUN3ME2xOk46ODN{IN88US=>NY\JUZE{W0GQR1XS
RKONHnUN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTF5LkC3OFgh|ryPNF3zWVFUSU6JRWK=
MZ2-MELNYX4XmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrRfIxKSzVyPUG3MlE{OyEQvF2=MWfTRW5ITVJ?
NCI-H1573M1fmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTF5LkK4NlYh|ryPM3rJSnNCVkeHUh?=
NCI-H1581NX\3OFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTF5LkS0NVEh|ryPMVfTRW5ITVJ?
NCI-H747NHXpbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2ryd2lEPTB;MUeuOVI6PyEQvF2=MVXTRW5ITVJ?
SW1783NHLwNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTF5Lk[0NVUh|ryPMYDTRW5ITVJ?
Calu-6M3HqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF5Lk[3PFIh|ryPNV;rRlJNW0GQR1XS
SF268MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\U[GlEPTB;MUeuOlk3QSEQvF2=Mmq2V2FPT0WU
ES8MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXXOZFKSzVyPUG3Mlg2QTNizszNNYP6R2tNW0GQR1XS
KM-H2Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjzXGw3UUN3ME2xO{46PDFzIN88US=>NELK[pRUSU6JRWK=
D-502MGMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTF5Lkm4NFgh|ryPMnjTV2FPT0WU
HLEM4DOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYP3W3lwUUN3ME2xPE4{OTR6IN88US=>MVXTRW5ITVJ?
SW982M2T0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTF6LkSwO|Uh|ryPM{DlcnNCVkeHUh?=
MDA-MB-361NU\uN|FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTF6LkW1PFgh|ryPMYfTRW5ITVJ?
NCI-H1563MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjDUFY6UUN3ME2xPE44OTJ2IN88US=>MmrFV2FPT0WU
MFE-280NV3tdo9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPSb2ZKSzVyPUG4MlczQTNizszNNFfkOZZUSU6JRWK=
U251M3vKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoexTWM2OD1zOD63N|Q4KM7:TR?=NUTxdYxbW0GQR1XS
KNS-42NHrxdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoS2TWM2OD1zOD64NFE2KM7:TR?=MV\TRW5ITVJ?
U-266M4PQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoG3TWM2OD1zOD64OlQ6KM7:TR?=MUHTRW5ITVJ?
OVCAR-8MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfPTWM2OD1zOD65Nlc3KM7:TR?=NGHEdVhUSU6JRWK=
MFH-inoNEL0UlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jrRmlEPTB;MUiuPVY3QSEQvF2=Mn;RV2FPT0WU
D-263MGNVGxcXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPEcVFKSzVyPUG5MlAyPzJizszNMWjTRW5ITVJ?
NCI-H1437MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3q5VGlEPTB;MUmuNFQ3PyEQvF2=NFrR[VdUSU6JRWK=
NCI-H1048NVvR[VhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1m5R2lEPTB;MUmuNlMzPiEQvF2=NGjQenlUSU6JRWK=
NCI-H446MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTF7LkO1PFkh|ryPNYPmenJtW0GQR1XS
NCI-N87MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjTNYFLUUN3ME2xPU42QTl{IN88US=>MnT2V2FPT0WU
WM-115NGftZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDvWFVKSzVyPUG5MlY4PzRizszNMn24V2FPT0WU
HuH-7NFewTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXRTWM2OD1zOT63OFIyKM7:TR?=NF\UcVRUSU6JRWK=
NCI-H650M3vse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjLXldKSzVyPUG5Mlc2ODhizszNNVrFS40{W0GQR1XS
TYK-nuNEXDSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXGTWM2OD1zOT64N|c5KM7:TR?=NHPrPWtUSU6JRWK=
BeckerMmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{X4N2lEPTB;MUmuPFU1PyEQvF2=MYfTRW5ITVJ?
BB49-HNCM{\oVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTF7LkmyJO69VQ>?M{HHOHNCVkeHUh?=
HGC-27NU\keZFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXTTWM2OD1{MD6xN|k1KM7:TR?=NUL1VWlTW0GQR1XS
SiHaM1ix[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJyLkO3NVIh|ryPNFTRbmNUSU6JRWK=
LB2518-MELNVLjeldVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTWTFc1UUN3ME2yNE4{PzN7IN88US=>MlH2V2FPT0WU
TE-5MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\1cGlEPTB;MkCuO|Q5OiEQvF2=M4S4cXNCVkeHUh?=
IST-SL1NIiw[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHPZ4JkUUN3ME2yNE44QDd7IN88US=>MULTRW5ITVJ?
A375NWfuVmtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTJzLkC1Olch|ryPMXfTRW5ITVJ?
MC116MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7pTWM2OD1{MT6wO|I{KM7:TR?=MV\TRW5ITVJ?
GI-1NH[2bmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTVTWM2OD1{MT6xO{DPxE1?NFPGSnlUSU6JRWK=
HOP-62Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDJelAzUUN3ME2yNU4zPzh2IN88US=>M1mxc3NCVkeHUh?=
PA-1M4X1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\nV4ROUUN3ME2yNU4zPzh5IN88US=>MXXTRW5ITVJ?
HTNVvPTlQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\PeWlEPTB;MkGuOFM{OSEQvF2=NF;BcJRUSU6JRWK=
HUTU-80NH7zbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTJzLkSzN|Yh|ryPNYO5eYZ3W0GQR1XS
NCI-H1975NYjY[IFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTJzLkS2NUDPxE1?MV\TRW5ITVJ?
GAKNH;lXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3:zO2lEPTB;MkGuOFk6KM7:TR?=NE\3VVFUSU6JRWK=
SK-N-ASM1H2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrWWnZKSzVyPUKxMlU3OTlizszNMmThV2FPT0WU
OE33NFjIb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzab41GUUN3ME2yNU43ODR4IN88US=>M3m3T3NCVkeHUh?=
YKG-1NEHYUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTJzLk[1OFUh|ryPNEHqNYRUSU6JRWK=
CAL-85NGezR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1iwUWlEPTB;MkGuPVMxPSEQvF2=NIjjbnRUSU6JRWK=
NCI-H2347NETFcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DjTWlEPTB;MkGuPVQzQCEQvF2=MmDxV2FPT0WU
PANC-08-13MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjaO4J1UUN3ME2yNk4xOTF7IN88US=>MlrjV2FPT0WU
SK-N-FIMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTJ{LkOwO|Qh|ryPNFHkdG5USU6JRWK=
NEC8MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFezbFRKSzVyPUKyMlUxPzhizszNMn7vV2FPT0WU
AN3-CANEL2fVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTJ{Lk[wPFQh|ryPMnn4V2FPT0WU
HuO9MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzZZ45OUUN3ME2yNk44Ozl4IN88US=>MYPTRW5ITVJ?
COLO-800NFvrc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LSOWlEPTB;MkKuO|Y2OyEQvF2=MknjV2FPT0WU
HT-29NFzMV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTJ{Lki4NlMh|ryPMmnmV2FPT0WU
OC-314M3nJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHQdohKSzVyPUKyMlg5PDVizszNM1[0bXNCVkeHUh?=
G-401M3nZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWraN45xUUN3ME2yN{4xPDZ{IN88US=>M1n4dHNCVkeHUh?=
Saos-2NVSwOXVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDuS|F7UUN3ME2yN{42OTh{IN88US=>NFT1c4FUSU6JRWK=
UACC-62MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTJ|LkW4N|Mh|ryPM1uzVnNCVkeHUh?=
D-247MGNHjqe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M16yTGlEPTB;MkOuO|k{QSEQvF2=MUXTRW5ITVJ?
COLO-741MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITo[XNKSzVyPUKzMlk2PjVizszNM2jjbXNCVkeHUh?=
ES3M2jkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfGS3BKSzVyPUK0MlAxOjNizszNMU\TRW5ITVJ?
LNCaP-Clone-FGCNH3tWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXexOoxkUUN3ME2yOE4xOjFzIN88US=>NITM[lJUSU6JRWK=
SW1710NH7pVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJ2LkG1NFYh|ryPNWr1OpBwW0GQR1XS
LU-99ANEHTTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrBRYZKSzVyPUK0MlE5PDFizszNMl3MV2FPT0WU
HOP-92NGDKPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rSbmlEPTB;MkSuO|I2KM7:TR?=NGDIZlBUSU6JRWK=
LS-123NH\TRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJ2Lkm2NVQh|ryPMn7iV2FPT0WU
T84MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NESyUJdKSzVyPUK0Mlk4PjVizszNMVrTRW5ITVJ?
HCT-116MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTJ3LkSxPFYh|ryPNVi4ZnlFW0GQR1XS
M14M4P5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7ZNZZKSzVyPUK1MlQ1PDdizszNMnmzV2FPT0WU
OCUB-MNF7ZRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjZOFBKSzVyPUK1MlQ1PTZizszNMXLTRW5ITVJ?
MKN45NGH5T4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLVZmhXUUN3ME2yOU43OzF3IN88US=>NEDQcVRUSU6JRWK=
LCLC-97TM1MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfGTWM2OD1{NT63Nlg2KM7:TR?=MnHDV2FPT0WU
RVH-421MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfZU4VjUUN3ME2yOU45OTZzIN88US=>M33TUHNCVkeHUh?=
NKS-81-FDNVnJ[VRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LJd2lEPTB;MkWuPVAzOSEQvF2=MmnqV2FPT0WU
NCI-H596NEmxSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3BTWM2OD1{Nj6wOFg4KM7:TR?=M2rDbHNCVkeHUh?=
GB-1MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXsR3VnUUN3ME2yOk4yQDd7IN88US=>NIL2OFdUSU6JRWK=
ZR-75-30MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDmR5FKSzVyPUK2MlIzQTdizszNMUjTRW5ITVJ?
U-2-OSNF3z[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJ4LkO3OVch|ryPMonEV2FPT0WU
HuP-T3MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFP6ZXhKSzVyPUK2MlYyODJizszNMkDDV2FPT0WU
MOLT-16M3i2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M161R2lEPTB;Mk[uOlE3PiEQvF2=MXPTRW5ITVJ?
U-87-MGMkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrOeGJ[UUN3ME2yOk44PDN6IN88US=>NYC0[VZHW0GQR1XS
8505CM1TYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvqfoRKSzVyPUK2MlkyOjZizszNNH\TXnlUSU6JRWK=
SK-MEL-3NETuPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEX1SWZKSzVyPUK2Mlk5OjhizszNM4jFUXNCVkeHUh?=
COLO-824M3\uUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTJ5LkKxPVUh|ryPMoewV2FPT0WU
EW-1M3r2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTJ5LkO1OVQh|ryPM1T1UnNCVkeHUh?=
UACC-257NFvjOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;1TWM2OD1{Nz6zPFA1KM7:TR?=NEK3NWxUSU6JRWK=
Hs-578-TNXi3N4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1iycWlEPTB;MkeuOVI6QSEQvF2=MknLV2FPT0WU
UACC-893M{j1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfYcWhKSzVyPUK3MlY3OzFizszNMVzTRW5ITVJ?
MHH-NB-11MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDTTGt{UUN3ME2yO{45ODB5IN88US=>NIn5T25USU6JRWK=
KYSE-410MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTJ6LkK3O|kh|ryPNYDoRZlXW0GQR1XS
SF126MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTBOZhEUUN3ME2yPE44PDN3IN88US=>NYH2SVN[W0GQR1XS
HT-144NEO5RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjKTWM2OD1{OT6zN|YzKM7:TR?=NXXNXWdjW0GQR1XS
SW1573NYTQ[201T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfiTWM2OD1{OT6zOVA6KM7:TR?=MkHRV2FPT0WU
SW620MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\uU4Z{UUN3ME2yPU4{PjRzIN88US=>MnvHV2FPT0WU
SCHMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTJ7Lki4N|Eh|ryPM4C0bXNCVkeHUh?=
EW-22NELZfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHGZnZKSzVyPUOwMlE6PjlizszNM4W3TXNCVkeHUh?=
H4NFLmcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfVOolUUUN3ME2zNE41PjV2IN88US=>NHe2[llUSU6JRWK=
CAS-1NXHufI03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXJTWM2OD1|MD63PFU6KM7:TR?=NYm3b|BWW0GQR1XS
MG-63Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTCTWM2OD1|MD64OFc5KM7:TR?=NHvUSIJUSU6JRWK=
MDA-MB-415MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXvd|FKSzVyPUOxMlE4PTNizszNNVX0dIZCW0GQR1XS
NCI-H1395MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTNzLkKzNlgh|ryPMkWyV2FPT0WU
Ca-SkiM4TqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLKTWM2OD1|MT6zNVc4KM7:TR?=NUH2[5FVW0GQR1XS
BxPC-3MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHvO|dKSzVyPUOxMlM4OjlizszNNILCfGZUSU6JRWK=
A3-KAWNGrjdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDTNGhRUUN3ME2zNU41PDdzIN88US=>M3n1cHNCVkeHUh?=
T-24MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;rXGJMUUN3ME2zNU44OzZ{IN88US=>NGrLcFNUSU6JRWK=
NCI-H2029NEXUZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LRO2lEPTB;M{GuO|c3PSEQvF2=Mk\kV2FPT0WU
YAPCMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTN{LkC0NFch|ryPNGjsOI5USU6JRWK=
SK-MEL-2MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTN{LkC1NkDPxE1?NIHQb3BUSU6JRWK=
LS-513NIe4cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTN{LkGxPFch|ryPMVPTRW5ITVJ?
AsPC-1M3zycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LJbGlEPTB;M{KuN|YxPSEQvF2=MUnTRW5ITVJ?
KYSE-150M1[5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTN{LkO3O|Mh|ryPNXT3UpJtW0GQR1XS
NCI-H520NELCeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHmTWM2OD1|Mj60OFgzKM7:TR?=NEjo[2NUSU6JRWK=
JEG-3M2L3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPFV2dOUUN3ME2zN{4xQTdzIN88US=>NWrG[pFlW0GQR1XS
GMS-10NHnjZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvq[WtKUUN3ME2zN{4{ODB2IN88US=>MmLCV2FPT0WU
HT-1080M4fOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrwRZl6UUN3ME2zN{4{QSEQvF2=MXvTRW5ITVJ?
NCI-H1651Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrRTWM2OD1|Mz6zPVYh|ryPNXjSepk6W0GQR1XS
NCI-H2122NGmyVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;tOGlEPTB;M{OuOVU4PCEQvF2=NGr1WplUSU6JRWK=
ES5Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rZRmlEPTB;M{OuO|I6OiEQvF2=MkDKV2FPT0WU
8305CNXPmeW1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXaU|JKSzVyPUOzMlk6OzdizszNNHi2cmRUSU6JRWK=
KM12MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlf4TWM2OD1|ND6wOFc5KM7:TR?=Ml;rV2FPT0WU
HCT-15M3f4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HiOmlEPTB;M{SuNVI4KM7:TR?=MkfFV2FPT0WU
OVCAR-5NIHaTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fkbGlEPTB;M{SuNlE5OiEQvF2=M175XXNCVkeHUh?=
NCI-H2291MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHwXZljUUN3ME2zOE4zPDd{IN88US=>MULTRW5ITVJ?
CP50-MEL-BM4TvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrSdHpKSzVyPUO0MlY2QTJizszNNX7hTnh[W0GQR1XS
C-33-ANEP0[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTYSo1iUUN3ME2zOE43QDV5IN88US=>MlSzV2FPT0WU
NCI-H2452MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvYV5dKSzVyPUO0Mlc5QDJizszNMmTYV2FPT0WU
MDA-MB-157MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\lb2lEPTB;M{SuPFE6OyEQvF2=MX;TRW5ITVJ?
LN-405Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TiVmlEPTB;M{WuOFMxQCEQvF2=MlmxV2FPT0WU
MDA-MB-231NX;YTFZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\ITWM2OD1|NT61NFU1KM7:TR?=MWnTRW5ITVJ?
EW-24NYD5NFNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTN3Lk[zN|Uh|ryPM1r5SnNCVkeHUh?=
MKN28NF\ofllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfaO|lKSzVyPUO1MlgzOzZizszNNXG0XJBjW0GQR1XS
KINGS-1NVTSfJBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljxTWM2OD1|NT64OFM1KM7:TR?=NW\xbJl5W0GQR1XS
LC-2-adMmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfoXJZDUUN3ME2zOk43QTlizszNNWfIU5FqW0GQR1XS
IGR-1Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWC0PYZsUUN3ME2zOk44ODd3IN88US=>NESwVJdUSU6JRWK=
SW626NUXBUZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYCzSVdGUUN3ME2zO{4xPDF5IN88US=>MnvZV2FPT0WU
ONS-76MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDuRXdiUUN3ME2zO{4yOzB7IN88US=>NIj3OHVUSU6JRWK=
T98GMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljiTWM2OD1|Nz64OlM2KM7:TR?=MmjlV2FPT0WU
NB14NV7DXnY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjyTWM2OD1|OD60OVQ1KM7:TR?=MUPTRW5ITVJ?
D-423MGM3;vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLjeGc3UUN3ME2zPE41QDZ7IN88US=>MUXTRW5ITVJ?
NCI-H510AMmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXi1cZozUUN3ME2zPE43PDVzIN88US=>NXLK[FN5W0GQR1XS
NMC-G1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\GSVJKSzVyPUO4MlczOjJizszNM1fmdXNCVkeHUh?=
SW948NV6zdWptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTN6Lki5OFkh|ryPNWG2cGFJW0GQR1XS
MFM-223NYTHb5J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfVW2Z5UUN3ME2zPE46PDNzIN88US=>MWXTRW5ITVJ?
PAN1M{PHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTN6Lkm5NVkh|ryPMoDaV2FPT0WU
MZ7-melM13MSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfqcWpzUUN3ME2zPU4yOTl7IN88US=>MlfJV2FPT0WU
COLO-679MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkT0TWM2OD1|OT65O|A5KM7:TR?=NXq2V4pOW0GQR1XS
SW872MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPVR4JKSzVyPUSwMlIxOzFizszNMX7TRW5ITVJ?
HT-1197NU\WR5JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrDNGdKSzVyPUSwMlI5PjlizszNMnHJV2FPT0WU
ES6NIWwNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDsTpRKSzVyPUSwMlQ2PTJizszNM1TmR3NCVkeHUh?=
SNU-387NFq5WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfDSW9SUUN3ME20NE45OjN6IN88US=>MkfNV2FPT0WU
T47DMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLuS|FsUUN3ME20NU4xOTl{IN88US=>M131fHNCVkeHUh?=
G-402NUXBNm91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2[4cGlEPTB;NEGuNFgxQSEQvF2=MXnTRW5ITVJ?
MZ1-PCMlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnQ[|NDUUN3ME20NU45OSEQvF2=M2j0d3NCVkeHUh?=
SW1417Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjUNo5uUUN3ME20Nk4{ODNizszNMlq4V2FPT0WU
RERF-LC-MSNVy5Zoh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTR{LkWwPFch|ryPNITtZZJUSU6JRWK=
SF539M4n4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfGcoY{UUN3ME20Nk42PTJ7IN88US=>M4nWOHNCVkeHUh?=
ESS-1MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWC1UJh7UUN3ME20N{42PTV6IN88US=>M{K3R3NCVkeHUh?=
RO82-W-1NUX2OVJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7tSHZiUUN3ME20N{43OTV|IN88US=>NV\0[G02W0GQR1XS
S-117NUHmNWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTR|Lk[5OVgh|ryPMV7TRW5ITVJ?
SW756MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTR|LkiyOFIh|ryPNFKzTohUSU6JRWK=
CP66-MELNEXTOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLCTWM2OD12NT63NVQ{KM7:TR?=NVXJS4h[W0GQR1XS
H-EMC-SSMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;Gb4s2UUN3ME20OU44Pjl|IN88US=>NYnnWpVbW0GQR1XS
NCI-H2052NGHYS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPlTWM2OD12NT65NFI4KM7:TR?=NFL6UopUSU6JRWK=
SW684M3Hwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIT1fZZKSzVyPUS3MlAxQDFizszNMmnhV2FPT0WU
HCC1569MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHINnlKSzVyPUS3MlE3PThizszNNEHwSFJUSU6JRWK=
KGNMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjuTWM2OD12Nz6zN|EyKM7:TR?=NW\mNnh7W0GQR1XS
LCLC-103HM1LZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrLcVZKSzVyPUS3MlQ1ODRizszNM4HZWnNCVkeHUh?=
SW780NH\HbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlG4TWM2OD12Nz62N|UyKM7:TR?=M4XJPHNCVkeHUh?=
NCI-H1703M2\2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlH6TWM2OD12OD6zN|UzKM7:TR?=NYHp[IR4W0GQR1XS
HCC1395Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LhNWlEPTB;NEiuO|Q{OiEQvF2=M3ntWHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. [3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. [4]
Features A potent EGFR tyrosine kinase inhibitor.

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines NR6, NR6M and NR6W cells
Concentrations 0-2 μM
Incubation Time 72 hours
Method Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

Animal Study: [3]

Animal Models Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation 0.5% polysorbate
Dosages 100 mg/kg
Administration Once daily by oral administration (0.1 mL/10 g body weight) for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pedersen MW, et al. Br J Cancer. 2005, 93(8), 915-923.

[2] Moasser MM, et al. Cancer Res. 2001, 61(19), 7184-7188.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02740894 Completed Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ? Taipei Veterans General Hospital, Taiwan February 2016 --
NCT02347839 Recruiting Lung Cancer Sun Yat-sen University January 2016 Phase 2
NCT02588261 Recruiting Non-small Cell Lung Cancer (NSCLC) Astellas Pharma Global Development, Inc.|Astellas Pharma Inc November 2015 Phase 3
NCT02326285 Recruiting Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage I  ...more Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage IIIB|Activating EGFR Mutation|NSCLC AIO-Studien-gGmbH|AstraZeneca November 2015 Phase 2|Phase 3
NCT02321293 Recruiting Lung Cancer Lady Davis Institute|Jewish General Hospital August 2015 Phase 1

view more

Chemical Information

Download Gefitinib (ZD1839) SDF
Molecular Weight (MW) 446.90
Formula

C22H24ClFN4O3

CAS No. 184475-35-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 89 mg/mL (199.14 mM)
Ethanol 4 mg/mL (8.95 mM)
Water <1 mg/mL (<1 mM)
In vivo 5% DMSO+corn oil 2.5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

Customer Product Validation(11)


Click to enlarge
Rating
Source Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck
Method qPCR analysis
Cell Lines glioblastoma cell lines
Concentrations 5 μM, 50 ng/ml
Incubation Time 6 h
Results We perturbed the activity of the EGFR by activating it using one of its ligands (EGF) and inhibiting it with a selective EGFR inhibitor (Gefitinib). As readout, we measured the transcriptional effect on SOCS2 (a modulator of STAT signaling), NR2E1(also known as TLX , a transcription factor believed to be important for neural stem cell renewal), yielding results compatible with a coupling between hub perturbation and transcriptional response.

Click to enlarge
Rating
Source Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines MEFs
Concentrations 1 μM
Incubation Time 48 h
Results We found that gefitinib, a specific EGFR inhibitor, almost completely recapitulated the results obtained by genistein (Figure a). Consistent with these results, we observed increased EGFR phosphorylation within 2 days of RECK depletion , with insignificant change in its protein amount (Figure b).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Gefitinib and other inhibitors all tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells)

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells .

Click to enlarge
Rating
Source J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck
Method Cytotoxicity assay
Cell Lines NK-92 cells/ lung cancer cells
Concentrations 10 μM
Incubation Time 24 h
Results Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors (erlotinib/gefitinib) and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells.

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Proliferation assay, Plaque reduction test, Western blot, Real-time PCR
Cell Lines Hep2 cells
Concentrations 0.01-1000 μM
Incubation Time
Results While for Gefitinib concentrations between 100 μM and 0.01 μM the proliferation rate was almost 100% of the controls, only at concentrations of 1000 μM a slight (24%) decline in proliferation was observed (Fig.A). IC50 values of Gefitinib for plaque size reduction were calculated by dividing plaque size by total size of one tissue culture plate well for each compound concentration. A non-linear regression fit curve analysis from the calculated values revealed for plaque size reduction an IC50 value of 4.93μM for Gefitinib(Fig. B).The analysis of phosphorylated EGFR and of the downstream signaling kinases ERK1/2 in cell lysates of the assay confirmed the dose dependency of the antiviral effect of Gefitinib. Kinase activ-ities were completely suppressed at concentrations above 1μM as determined by Western blot analysis. VACV proteins were not detectable between 10 μM and 100 μM in Western blot analysis anymore (Fig. C).

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Immunofluorescence
Cell Lines Hep2 cells
Concentrations 0.01-1000 nM
Incubation Time 96 h
Results As shown in Fig. A, an immunofluorescent staining of a plaque reduction test was performed 96 h after viral infection. VACV infected cells were treated with 1000 μM, 1 μM or 0.01 μM Gefitinib and compared to uninfected cells after 96 h incubation. At concentrations of 1000 μM Gefitinib virus induced plaques were rarely found in cell culture and infected cells only could be identified by fluorescent staining of orthopoxvirus proteins (green) but not by light microscopy. At this Gefitinib concentration EGFR phosphorylation was completely suppressed in the cells and even the uninfected, untreated control cells show a stronger pEGFR signal (control, red). Occasionally found plaques, visible by flourescence microscopy only, showed a very compact shape with minimal disruption in its center. At the lower Gefitinib concentrations plaques showed an increasing number of infected and pEGFR positive cells (merge, yellow) and a surround-ing small zone of solely pEGFR positive cells (red). The lower the Gefitinib concentration the more plaques with a disrupted center were observed (1μM and 0.01μM). Most of the cells localized in the center of the plaque were positive for orthopoxvirus infection but negative for pEGFR ( Fig. B).

Click to enlarge
Rating
Source Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck
Method Immunoprecipitation/Western blotting
Cell Lines
Concentrations 5 μM
Incubation Time 0-1 h
Results In the presence of the EGFR tyrosine kinase inhibitor Z D1839 (Iressa) revealed that the observed increase in binding between PCM1 and Azi1 is specific to EGFs timulation and requires E GFR activation.

Click to enlarge
Rating
Source Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck
Method CEER assay
Cell Lines H358 cell line
Concentrations 0.01-10 μM
Incubation Time 4 h
Results HER1 and/or HER2 pathway-activated cell lines, H358 , had their activation blocked by the HER1/2 kinase inhibitors Gefitinib.

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-5 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck
Method MTT assay
Cell Lines H1299 cells, H358 cells, H25 cells, HCC827 cells
Concentrations 0-400 nM
Incubation Time 72 h
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Gefitinib (ZD1839) | Gefitinib (ZD1839) ic50 | Gefitinib (ZD1839) price | Gefitinib (ZD1839) cost | Gefitinib (ZD1839) solubility dmso | Gefitinib (ZD1839) purchase | Gefitinib (ZD1839) manufacturer | Gefitinib (ZD1839) research buy | Gefitinib (ZD1839) order | Gefitinib (ZD1839) mouse | Gefitinib (ZD1839) chemical structure | Gefitinib (ZD1839) mw | Gefitinib (ZD1839) molecular weight | Gefitinib (ZD1839) datasheet | Gefitinib (ZD1839) supplier | Gefitinib (ZD1839) in vitro | Gefitinib (ZD1839) cell line | Gefitinib (ZD1839) concentration | Gefitinib (ZD1839) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us